September 04, 2025

'No Standard of Care' for GLP-1 Weaning

Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates

KFF Health News

September 04, 2025

Medical Oddities: Sugar-Free, Cognition Fee?

This week: sugar-free brain costs, deadly selfies, tea for liver, knee creaks, and phone drama.

Conexiant

September 04, 2025

AI Tool Detects Lupus From Eye Scans

DeepSLE uses retinal images to identify systemic lupus erythematosus and related complications with high accuracy across diverse populations, outperforming physicians in a prospective comparison.

Conexiant

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 02, 2025

New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response

The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.

Conexiant

August 29, 2025

Updated Approaches Strengthen Osteoporosis Risk Management

Updated osteoporosis management emphasizes improved risk prediction, lifestyle strategies, and stepwise therapy to reduce future fractures.

Conexiant

August 28, 2025

Late Dinners, Fragile Bones?

Fracture risk varies by site, with distal forearm outcomes diverging from hip, vertebral, and humeral patterns

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

August 27, 2025

High Brain Pain Activity Tied to Better RA Outcomes

"These data highlight the role of subjective patient-related parameters in the response to cytokine inhibition and suggest that a high-volume representation of the disease in the CNS—involving more frontal-associative brain circuits—increases the likelihood to respond to TNF inhibitor.

Conexiant